Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) disclosed that it bought back 24,000 H shares on 14 July 2026 via the Hong Kong Stock Exchange under its existing repurchase mandate.

The transaction was executed at prices ranging from HKD 5.90 to HKD 6.10 per share, with a volume-weighted average cost of HKD 5.98. Total consideration amounted to HKD 0.14 million.

Following the repurchase, the number of treasury shares rose from 5.04 million to 5.06 million. Issued shares outstanding (excluding treasury shares) fell marginally to 240.34 million, representing a 0.00999% decrease. The company’s total issued share count remains unchanged at 245.40 million.

The buy-back forms part of the mandate approved on 15 June 2026, which allows Jiuyuan Gene to repurchase up to 24.15 million shares. Aggregate repurchases under this authority now stand at 1.18 million shares, equivalent to 0.49% of the issued share capital on the mandate date.

In line with Hong Kong listing rules, Jiuyuan Gene is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 August 2026.